Share this video  

ESMO WCGIC 2020 | Ad-CEA vaccine plus avelumab vs mFOLFOX6-based standard care in untreated metastatic CRC

Jason Redman, MD, National Cancer Institute, Bethesda, MD, discusses the randomized Phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).